Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Tipo del documento
Publication year range
1.
Mem Inst Oswaldo Cruz ; 113(4): e170484, 2018 Feb 05.
Artículo en Inglés | MEDLINE | ID: mdl-29412345

RESUMEN

BACKGROUND: Candida glabrata ranks second in epidemiological surveillance studies, and is considered one of the main human yeast pathogens. Treatment of Candida infections represents a contemporary public health problem due to the limited availability of an antifungal arsenal, toxicity effects and increasing cases of resistance. C. glabrata presents intrinsic fluconazole resistance and is a significant concern in clinical practice and in hospital environments. OBJECTIVE: The aim of this study was to characterise the azole resistance mechanism presented by a C. glabrata clinical isolate from a Brazilian university hospital. METHODS: Azole susceptibility assays, chemosensitisation, flow cytometry and mass spectrometry were performed. FINDINGS: Our study demonstrated extremely high resistance to all azoles tested: fluconazole, voriconazole, posaconazole and itraconazole. This isolate was chemosensitised by FK506, a classical inhibitor of ABC transporters related to azole resistance, and Rhodamine 6G extrusion was observed. A mass spectrometry assay confirmed the ABC protein identification suggesting the probable role of efflux pumps in this resistance phenotype. MAIN CONCLUSIONS: This study emphasizes the importance of ABC proteins and their relation to the resistance mechanism in hospital environments and they may be an important target for the development of compounds able to unsettle drug extrusion.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/efectos de los fármacos , Antifúngicos/farmacología , Azoles/farmacología , Candida glabrata/efectos de los fármacos , Transportadoras de Casetes de Unión a ATP/metabolismo , Candida glabrata/metabolismo , Farmacorresistencia Fúngica , Citometría de Flujo , Humanos , Espectrometría de Masas
2.
Mem. Inst. Oswaldo Cruz ; 113(4): e170484, 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-894913

RESUMEN

BACKGROUND Candida glabrata ranks second in epidemiological surveillance studies, and is considered one of the main human yeast pathogens. Treatment of Candida infections represents a contemporary public health problem due to the limited availability of an antifungal arsenal, toxicity effects and increasing cases of resistance. C. glabrata presents intrinsic fluconazole resistance and is a significant concern in clinical practice and in hospital environments. OBJECTIVE The aim of this study was to characterise the azole resistance mechanism presented by a C. glabrata clinical isolate from a Brazilian university hospital. METHODS Azole susceptibility assays, chemosensitisation, flow cytometry and mass spectrometry were performed. FINDINGS Our study demonstrated extremely high resistance to all azoles tested: fluconazole, voriconazole, posaconazole and itraconazole. This isolate was chemosensitised by FK506, a classical inhibitor of ABC transporters related to azole resistance, and Rhodamine 6G extrusion was observed. A mass spectrometry assay confirmed the ABC protein identification suggesting the probable role of efflux pumps in this resistance phenotype. MAIN CONCLUSIONS This study emphasizes the importance of ABC proteins and their relation to the resistance mechanism in hospital environments and they may be an important target for the development of compounds able to unsettle drug extrusion.


Asunto(s)
Azoles/uso terapéutico , Candida glabrata/efectos de los fármacos , Candida glabrata/metabolismo , Espectrometría de Masas , Citometría de Flujo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda